---
document_datetime: 2025-05-19 11:04:09
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bylvay-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: bylvay-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.7554369
conversion_datetime: 2025-12-28 03:11:59.095496
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Bylvay

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                             |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------|
| II/0022/G            | This was an application for a group of variations. A grouped application including two type II variations: - Update of sections 4.2, 4.4, 4.8, and 5.1 of the SmPC based on the clinical study report for the completed 72 weeks of Study A4250-008; an open- | 13/03/2025                          | 02/05/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion Bylvay-H-C-004691-II- 0022/G. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | efficacy and safety of odevixibat in children with PFIC (category 3 study in the RMP; MEA 002). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and the Package Leaflet. An updated RMP version 6.3 was included in this submission. - Submission of the clinical study report for Study A4250-J001; a Phase I PK study in healthy Japanese adult male patients. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             |                                                                                                                                                                                                                                                                 |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10949 /202407 | Periodic Safety Update EU Single assessment - odevixibat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/02/2025 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| S/0023              | 3rd annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/01/2025 | n/a        |             | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Bylvay should be maintained. |
| PSUSA/10949 /202401 | Periodic Safety Update EU Single assessment - odevixibat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/09/2024 | 22/11/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10949/202401.                                                                                                                      |
| II/0018             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 27/06/2024 | 24/07/2024 | SmPC and PL | SMPC section 4.2 Posology and Method of Administration is updated to include instructions for administration of Bylvay                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                     | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        | pellets in age-appropriate liquids in addition to the pre- existing instructions for administration in soft foods. The package leaflet is updated accordingly.                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0017              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 31/01/2024 | 16/02/2024 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| PSUSA/10949 /202307 | Periodic Safety Update EU Single assessment - odevixibat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/02/2024 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| S/0016              | 2nd annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/01/2024 | n/a        |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Bylvay should be maintained.                                                                                                                                                                                                                                                                         |
| PSUSA/10949 /202301 | Periodic Safety Update EU Single assessment - odevixibat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 31/08/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0013             | Update of sections 4.4, 4.5 and 4.6 of the SmPC in order to update an existing warning, add drug-drug interaction (DDI) information with oral contraceptives and update information for women of childbearing potential, based on study A4250-022 listed as a category 3 study in the RMP; this is an open-label, phase 1 DDI study to evaluate the interaction of odevixibat with oral lipophilic contraceptives in healthy volunteers. The Package Leaflet and the RMP vs 4.1 is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 12/05/2023 | 16/02/2024 | SmPC and PL            | Interaction study A4250-022 with a lipophilic combination oral contraceptive containing ethinyl estradiol (EE) (0.03 mg) and levonorgestrel (LVN) (0.15 mg) conducted in adult healthy females, concomitant use of odevixibat had no impact on the AUC of LVN and decreased the AUC of EE by 17%, which is not considered clinically relevant. Interaction studies with other lipophilic medicinal products have not been performed, therefore, an effect on the absorption of other fat-soluble medicinal products cannot be excluded. |

<div style=\"page-break-after: always\"></div>

|                     | data                                                                                                                                                                                                                                                                                                                                           |            |            |      |                                                                                                                                                                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0012             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                  | 13/03/2023 | n/a        |      |                                                                                                                                                                                                                                                                 |
| PSUSA/10949 /202207 | Periodic Safety Update EU Single assessment - odevixibat                                                                                                                                                                                                                                                                                       | 09/02/2023 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| S/0008              | 1st annual re-assessment                                                                                                                                                                                                                                                                                                                       | 15/12/2022 | n/a        |      | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Bylvay should be maintained. |
| IB/0009/G           | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 20/09/2022 | n/a        |      |                                                                                                                                                                                                                                                                 |
| PSUSA/10949 /202201 | Periodic Safety Update EU Single assessment - odevixibat                                                                                                                                                                                                                                                                                       | 01/09/2022 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| IB/0005             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                     | 09/06/2022 | n/a        |      |                                                                                                                                                                                                                                                                 |
| IB/0006             | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other                                                                                                                                                                                                                                  | 30/05/2022 | 31/05/2023 | SmPC |                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | variation                                                                                                                                                                                                                                             |            |     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0004 | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place            | 02/03/2022 | n/a |
| II/0001 | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                   | 11/11/2021 | n/a |
| IB/0002 | B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue | 05/10/2021 | n/a |